BioSig Technologies, Inc. (BSGM)
NASDAQ: BSGM · Real-Time Price · USD
1.340
+0.040 (3.08%)
At close: Dec 20, 2024, 4:00 PM
1.300
-0.040 (-2.99%)
After-hours: Dec 20, 2024, 7:59 PM EST
Company Description
BioSig Technologies, Inc., a medical technology company, focuses on deciphering the body’s electrical signals starting with heart rhythms.
It delivers unprecedented cardiac signal clarity, ending the reliance on mixed signals and reading between the lines.
The company’s product, the PURE EP Platform, provides real-time signal visualization allowing physicians to perform targeted cardiac ablation procedures with increased procedural efficiency and efficacy.
The company has a research agreement with Mayo Foundation to develop an AI- and machine learning-powered software for PURE EP system.
BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.
BioSig Technologies, Inc.
| Country | United States |
| Founded | 2009 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Anthony Amato |
Contact Details
Address: 55 Greens Farms Road, 1st Floor Westport, Connecticut 06880 United States | |
| Phone | 203 409 5444 |
| Website | biosig.com |
Stock Details
| Ticker Symbol | BSGM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001530766 |
| CUSIP Number | 09073N201 |
| ISIN Number | US09073N3008 |
| Employer ID | 26-4333375 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Anthony Amato | Chief Executive Officer, Chairman and Member of Advisory Board |
| Frederick D. Hrkac | President, Principal Executive Officer, Executive Vice President and Director |
| Ferdinand Groenewald | Interim Chief Financial Officer and Principal Accounting Officer |
| Dr. Budimir S. Drakulic Ph.D. | Chief Scientist |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 18, 2024 | 8-K | Current Report |
| Dec 18, 2024 | 424B5 | Filing |
| Dec 17, 2024 | EFFECT | Notice of Effectiveness |
| Dec 9, 2024 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Dec 6, 2024 | 8-K | Current Report |
| Nov 18, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Nov 18, 2024 | DEF 14A | Other definitive proxy statements |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | 8-K | Current Report |